MSOS
AdvisorShares Pure US Cannabis ETF
Price Chart
Latest Quote
$4.42
| Previous Close | $4.50 |
| Open | $4.50 |
| Day High | $4.53 |
| Day Low | $4.35 |
| Volume | 1,336,505 |
Fund Information
| Net Assets | $1.02B |
| Expense Ratio | 0.78% |
| Category | Miscellaneous Sector |
| Fund Family | AdvisorShares |
| Net Asset Value | $4.51 |
| Premium/Discount | -2.04% |
| Exchange | PCX |
📊 ETF Analysis
Company Data
Financial Ratios
Returns & Margins
Ownership
| Insider & Institutional transactions data not available |
Valuation Ratios
Analyst Data
Technical Indicators
| SMA20 | $5.01 |
| SMA50 | $4.81 |
| SMA200 | $4.42 |
| RSI | 44.24 |
| ATR | 0.3415 |
| Rel Volume | 0.17 |
Performance History
| Week | -8.49% |
| Month | -0.23% |
| Quarter | +16.32% |
| 6 Months | -9.43% |
| YTD | -7.72% |
| Year | +114.56% |
| 3 Years | -19.34% |
| 5 Years | -88.53% |
| 10 Years | -82.03% |
ETF Scoring Not Available
Exchange-traded funds (ETFs) are not scored using our fundamental analysis metrics, as they represent baskets of securities rather than individual companies.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-24 | $4.42 | 1,336,505 |
| 2026-06-23 | $4.50 | 7,554,100 |
| 2026-06-22 | $4.68 | 7,821,300 |
| 2026-06-18 | $4.99 | 7,511,300 |
| 2026-06-17 | $4.77 | 5,395,900 |
| 2026-06-16 | $4.83 | 6,058,900 |
| 2026-06-15 | $4.94 | 6,757,200 |
| 2026-06-12 | $5.04 | 7,588,600 |
| 2026-06-11 | $5.27 | 8,484,000 |
| 2026-06-10 | $5.36 | 6,762,600 |
| 2026-06-09 | $5.49 | 11,820,600 |
| 2026-06-08 | $5.75 | 9,891,200 |
| 2026-06-05 | $5.47 | 18,152,000 |
| 2026-06-04 | $5.10 | 11,236,300 |
| 2026-06-03 | $4.74 | 9,984,900 |
| 2026-06-02 | $5.05 | 6,078,400 |
| 2026-06-01 | $5.11 | 5,571,000 |
| 2026-05-29 | $4.92 | 6,040,500 |
| 2026-05-28 | $5.12 | 12,901,700 |
| 2026-05-27 | $4.65 | 3,744,400 |
| 2026-05-26 | $4.68 | 6,623,500 |
About AdvisorShares Pure US Cannabis ETF
The fund is an actively managed ETF that seeks to achieve its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that derive at least 50% of their net revenue from the marijuana and hemp business in the United States and in derivatives that have economic characteristics similar to such securities. It will concentrate at least 25% of its investments in the pharmaceuticals, biotechnology & life sciences industry group within the health care sector. The fund is non-diversified.
📰 Latest News
Cannabis Stocks Pop As Another U.S. Company Applies to List on NYSE
Moby • 2026-06-18T20:20:56Z
Trulieve Makes History as the First US Cannabis Company to Trade on the NYSE
Moby • 2026-06-10T17:01:15Z
MSOS Hits 2026 High: Which Cannabis Stock Could Light Up Portfolios Ahead Of DEA Hearing?
Stocktwits • 2026-06-09T04:06:10Z
TLRY Stock Back Into The Limelight – A Look At The Key Developments That Sparked Investor Optimism
Stocktwits • 2026-06-05T14:04:53Z
Robinhood Is Opening the Door to U.S. Cannabis With Reform On the Horizon
Moby • 2026-05-29T20:39:56Z
US Reclassifies Weed: Can Cannabis ETFs Give Your Portfolio a New High?
Zacks • 2026-05-14T17:06:00Z
Cannabis Rescheduling Could Unlock the Biggest MSO Rally Since 2021
24/7 Wall St. • 2026-05-06T13:24:22Z
Uncle Sam Is Giving Big Pot a Tax Break. But It’s Complicated.
Moby • 2026-05-05T19:09:56Z
Trump’s Rescheduling of Marijuana Is a Spark for Top Marijuana ETFs
MarketBeat • 2026-05-03T13:30:00Z
Top Performing Leveraged/Inverse ETFs: 04/26/2026
ETF Trends • 2026-04-28T18:49:11Z